TFS Global Newsletter, October 2017
- Home
- About us
- Services
- Divisions
- Expertise
- Therapeutic Expertise
- Key Therapeutic Areas
- Therapeutic Experts
- Special expertise
- Regulatory expertise
- Regulatory experts
- Case Studies
- Phase I Trial Maximum Dose Tolerance / Advanced Cancer Patients
- Rescue of a Global Phase III Orphan Drug Study for Hypoparathyroidism
- Double-Blind Global Study (USA +/India/ Europe in Cancer patients)
- Rescue of 'At-Risk' Trial H5N1 Vaccine Study
- TFS involved in European global customer’s pre-launch activities
- Careers
- News & Events
- Contact us
